Emerging Concepts for PI3K/mTOR Inhibition As a Potential Treatment for Osteosarcoma

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2016 Jul 22

PMID 27441088

Citations 18

Authors

Michael W Bishop

Katherine A Janeway

Affiliations

Soon will be listed here.

Abstract

Patients with metastatic and recurrent osteosarcoma fare poorly, and new therapeutic strategies are needed to improve survival. Several recent complementary genomic and pathway analyses of both murine and human osteosarcoma have revealed common aberrations of the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway in osteosarcoma. Preclinical data demonstrate that inhibition of PI3K and mTOR with either a combination of single agents or dual inhibiting compounds can decrease cell proliferation and induce cell cycle arrest and apoptosis. With a lack of available clinical agents active in osteosarcoma, PI3K/mTOR inhibition represents a potential vulnerability in osteosarcoma that warrants clinical investigation.

Citing Articles

Targeting the mitochondrial protein YME1L to inhibit osteosarcoma cell growth in vitro and in vivo.

Sun X, Shi C, Dai J, Zhang M, Pei D, Yang L Cell Death Dis. 2024; 15(5):346.

PMID: 38769124 PMC: 11106333. DOI: 10.1038/s41419-024-06722-6.

Evaluation of the Biological Effect of Non-UV-Activated Bergapten on Selected Human Tumor Cells and the Insight into the Molecular Mechanism of Its Action.

Bartnik M, Slawinska-Brych A, Mizerska-Kowalska M, Zdzisinska B Int J Mol Sci. 2023; 24(21).

PMID: 37958539 PMC: 10647757. DOI: 10.3390/ijms242115555.

HOXC13-driven TIMM13 overexpression promotes osteosarcoma cell growth.

Han Q, Yan P, Song R, Liu F, Tian Q Cell Death Dis. 2023; 14(7):398.

PMID: 37407582 PMC: 10322838. DOI: 10.1038/s41419-023-05910-0.

Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents inhibition of PI3K/Akt/mTOR signalling pathway.

Su Q, Xu B, Tian Z, Gong Z Acta Pharm. 2023; 72(3):389-402.

PMID: 36651540 DOI: 10.2478/acph-2022-0026.

ADCK1 is a potential therapeutic target of osteosarcoma.

Zhuo B, Zhu L, Yao C, Wang X, Li S, Wang R Cell Death Dis. 2022; 13(11):954.

PMID: 36371387 PMC: 9653483. DOI: 10.1038/s41419-022-05401-8.

References

Meyers P, Schwartz C, Krailo M, Kleinerman E, Betcher D, Bernstein M . Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23(9):2004-11. DOI: 10.1200/JCO.2005.06.031. View

Perry J, Kiezun A, Tonzi P, Van Allen E, Carter S, Baca S . Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014; 111(51):E5564-73. PMC: 4280630. DOI: 10.1073/pnas.1419260111. View

Fouladi M, Laningham F, Wu J, OShaughnessy M, Molina K, Broniscer A . Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol. 2007; 25(30):4806-12. DOI: 10.1200/JCO.2007.11.4017. View

Demetri G, Chawla S, Ray-Coquard I, Cesne A, Staddon A, Milhem M . Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013; 31(19):2485-92. DOI: 10.1200/JCO.2012.45.5766. View

Mirabello L, Troisi R, Savage S . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-43. PMC: 2813207. DOI: 10.1002/cncr.24121. View

Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz S . Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol. 2012; 30(20):2545-51. PMC: 3397787. DOI: 10.1200/JCO.2011.37.4546. View

Wagner L, Fouladi M, Ahmed A, Krailo M, Weigel B, Dubois S . Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014; 62(3):440-4. PMC: 4501773. DOI: 10.1002/pbc.25334. View

Briccoli A, Rocca M, Salone M, Guzzardella G, Balladelli A, Bacci G . High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol. 2009; 19(4):193-9. DOI: 10.1016/j.suronc.2009.05.002. View

Rodrigues H, Ke D, Lim J, Stephen B, Bellido J, Janku F . Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015; 33(3):700-9. DOI: 10.1007/s10637-015-0238-2. View

10.

Grignani G, Palmerini E, Ferraresi V, DAmbrosio L, Bertulli R, Asaftei S . Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2014; 16(1):98-107. DOI: 10.1016/S1470-2045(14)71136-2. View

11.

Chawla S, Staddon A, Baker L, Schuetze S, Tolcher A, DAmato G . Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2011; 30(1):78-84. DOI: 10.1200/JCO.2011.35.6329. View

12.

Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B . Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003; 21(10):2011-8. DOI: 10.1200/JCO.2003.08.132. View

13.

Gupte A, Baker E, Wan S, Stewart E, Loh A, Shelat A . Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res. 2015; 21(14):3216-29. PMC: 4506243. DOI: 10.1158/1078-0432.CCR-14-3026. View

14.

Schwartz G, Tap W, Qin L, Livingston M, Undevia S, Chmielowski B . Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013; 14(4):371-82. PMC: 3766955. DOI: 10.1016/S1470-2045(13)70049-4. View

15.

Penel-Page M, Ray-Coquard I, Larcade J, Girodet M, Bouclier L, Rogasik M . Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). BMC Cancer. 2015; 15:854. PMC: 4635968. DOI: 10.1186/s12885-015-1894-5. View

16.

Choy E, Hornicek F, Macconaill L, Harmon D, Tariq Z, Garraway L . High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer. 2011; 118(11):2905-14. PMC: 3272156. DOI: 10.1002/cncr.26617. View

17.

Moriarity B, Otto G, Rahrmann E, Rathe S, Wolf N, Weg M . A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet. 2015; 47(6):615-24. PMC: 4767150. DOI: 10.1038/ng.3293. View

18.

Pignochino Y, DellAglio C, Basirico M, Capozzi F, Soster M, Marchio S . The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res. 2013; 19(8):2117-31. DOI: 10.1158/1078-0432.CCR-12-2293. View

19.

Schuetze S, Zhao L, Chugh R, Thomas D, Lucas D, Metko G . Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer. 2012; 48(9):1347-53. DOI: 10.1016/j.ejca.2012.03.022. View

20.

Bielack S, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K . Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2008; 27(4):557-65. DOI: 10.1200/JCO.2008.16.2305. View